Published 3 days ago

FDA approves Eli Lilly’s Alzheimer’s drug Kisunla

The Food and Drug Administration has approved Eli Lilly's Alzheimer's drug donanemab, providing more treatment choices for the disease in the U.S.
The drug will be marketed as Kisunla and is authorized for early symptomatic Alzheimer's disease in adults.

Insights by Ground AI

Does this summary seem wrong?

0 Articles

All

Left

Center

Right

The Guardian

FDA approves second Alzheimer’s drug that can slow onset of disease

Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the diseaseFederal health authorities on Tuesday gave approval to an experimental new drug that has shown to delay the onset of Alzheimer’s disease in trials.Donanemab, manufactured by Eli Lilly, is the second medication that has won the blessing of the Food and Drug Administration (FDA) to treat patients showing early symptoms of the disease, most prom…

3 days ago·London, United Kingdom

Read Full Article

Reuters

US FDA approves Lilly's Alzheimer's drug

The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain-wasting disease.

3 days ago·United Kingdom

Read Full Article

CBC News

FDA approves new Alzheimer's drug, offering hope for slower cognitive decline

The U.S. Food and Drug Administration gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain-wasting disease.

3 days ago·Canada

Read Full Article

Associated Press News

FDA approves a second Alzheimer's drug that can modestly slow disease

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease. It's only the second drug that's been convincingly shown to slow the memory-destroying disease. The

3 days ago·United States

Read Full Article